Latest Discovery Laboratories Inc. Stories
WARRINGTON, Pa., May 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 9.5 million shares of its common stock under Discovery Labs' previously filed registration statement that was declared effective by the Securities and Exchange Commission on June 21, 2011. The offering remains subject to the underwriter's 30-day option to purchase up to an additional 1.425...
WARRINGTON, Pa., May 10, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 9.5 million shares of its common stock, at a price to the public of $1.50 per share for gross proceeds of $14.25 million. Net proceeds, after underwriting discount and other estimated fees and expenses payable by the Company, are expected to be approximately $13.2 million. The offering is expected to close on or about May 15,...
WARRINGTON, Pa., May 7, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the first quarter ended March 31, 2013 and also provides certain program updates. Selected operational updates: SURFAXIN(®): On April 15, 2013, the Company reported that it had received from the U.S. Food and Drug Administration (FDA) a response to a...
WARRINGTON, Pa., May 1, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to AFECTAIR(®), the Company's proprietary aerosol-conducting airway connector designed with the goal of simplifying and improving aerosolized medication delivery to infants requiring mechanical ventilation in the...
WARRINGTON, Pa., April 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has requested clarification and provided recommendations regarding the recently-updated product specifications for SURFAXIN(®). Discovery Labs plans to provide a response to the FDA within two months. FDA procedure provides up...
WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of...
WARRINGTON, Pa., March 6, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) will report fourth quarter 2012 results on Wednesday, March 13, 2013 before the open of the U.S. financial markets. The Company will also host a conference call at 10:00 a.m. ET that same day to discuss the fourth quarter financial results and other business updates. A question-and-answer session will follow management's remarks. To access the conference call and participate in the...
WARRINGTON, Pa., Feb. 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a secured loan facility with Deerfield Management Company, L.P. (Deerfield) for up to $30.0 million in financing. Deerfield is a leading healthcare investment firm with more than $3.5 billion of assets currently under management. "We are...
WARRINGTON, Pa., Jan. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced changes to its board of directors and appointed a new Chief Executive Officer (CEO). The following changes are effective immediately: W. Thomas Amick, age 70, has resigned as Chairman of the board of directors and CEO. Mr. Amick served on the board since March 2004, was...
WARRINGTON, Pa., Jan. 3, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has initiated the launch of its AFECTAIR(®) airway connector for infants receiving aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively). The AFECTAIR device simplifies the delivery of aerosolized medication to critical care...
